Dmk Pharmaceuticals Revenue Growth Rates (DMK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dmk Pharmaceuticals Corporation  (NASDAQ: DMK)
 

DMK's Revenue Growth by Quarter and Year

Dmk Pharmaceuticals's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DMK Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 0.01
2nd Quarter June 0.01
1st Quarter March 1.45
FY 1.47

DMKs Annual Revenue
Dmk Pharmaceuticals's Revenue in the fiscal year 2022 $ 4.76 millions
Dmk Pharmaceuticals's Revenue in the fiscal year 2021 $ 2.21 millions
Dmk Pharmaceuticals's Revenue in the fiscal year 2020 $ 16.53 millions
Dmk Pharmaceuticals's Revenue in the fiscal year 2019 $ 22.11 millions
Dmk Pharmaceuticals's Revenue in the fiscal year 2018 $ 15.09 millions




DMK Revenue third quarter 2023 Y/Y Growth Comment
Dmk Pharmaceuticals Corporation reported drop in Revenue in the third quarter 2023 by -99.4% to $ 0.01 millions, from the same quarter in 2022.
This represents worst decline in recent Company history.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 240 other companies have achieved higher Revenue growth. While Dmk Pharmaceuticals Corporation' s Revenue meltdown of -99.4% ranks overall at the positon no. 3955 in the third quarter 2023.


DMK Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - - - -34.3 %
3rd Quarter September -99.4 % 98.68 % -12.64 % -85.25 %
2nd Quarter June -75 % -96.88 % -67.43 % -31.77 %
1st Quarter March 26.09 % -17.27 % -70.17 % -5.09 %
FY   - 109.69 % -82.67 % -

Financial Statements
Dmk Pharmaceuticals's third quarter 2023 Revenue $ 0.01 millions DMK's Income Statement
Dmk Pharmaceuticals's third quarter 2022 Revenue $ 1.51 millions Quarterly DMK's Income Statement


DMK Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 36.42 % - 318.39 %
3rd Quarter September -9.38 % 3675 % -40.63 % -77.86 %
2nd Quarter June -99.31 % -96.52 % -7.91 % -15.67 %
1st Quarter March -29.61 % - -61.81 % -15.88 %
FY (Year on Year)   - 109.69 % -82.67 % -


Back to DMK Growth rate Comparisons >> Back to DMK Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #241
Healthcare Sector #630
Overall #3955

Revenue Y/Y Growth Statistics
High Average Low
98.13 % 0.5 % -99.4 %
(Sep 30 2022)   (Sep 30 2023)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #241
Healthcare Sector #630
Overall #3955
Revenue Y/Y Growth Statistics
High Average Low
98.13 % 0.5 % -99.4 %
(Sep 30 2022)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Dmk Pharmaceuticals's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3678.66 % 130.86 % -99.52 %
(Sep 30 2022)  


DMK's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Dmk Pharmaceuticals Corporation disclosed drop in Revenue from the second quarter by -9.38% to $ 0.01 millions, from $ 0.01 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Dmk Pharmaceuticals's Revenue growth quarter on quarter, overall rank is 350.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #125
Overall #350
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #125
Overall #350
Revenue Q/Q Growth Statistics
High Average Low
3678.66 % 130.86 % -99.52 %
(Sep 30 2022)  


DMK's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Dmk Pharmaceuticals Corporation disclosed drop in Revenue from the second quarter by -9.38% to $ 0.01 millions, from $ 0.01 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Dmk Pharmaceuticals's Revenue growth quarter on quarter, overall rank is 350.


Dmk Pharmaceuticals's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 3.53 $ 5.02 $ 5.05 $ 4.76 $ 1.54
Y / Y Revenue Growth (TTM) 128.81 % 531.74 % 148.93 % 109.6 % -78.2 %
Year on Year Revenue Growth Overall Ranking # 170 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -29.8 % -0.65 % 6.28 % 208.71 % 93.81 %
Seq. Revenue Growth (TTM) Overall Ranking # 1702 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Assuming the Dmk Pharmaceuticals's fiscal year would have ended in Sep 30 2023, Dmk Pharmaceuticals would have reprted above average annual Revenue surge of 128.81% year on year, of $ 4 millions.
This marks a slow-down of the companys growth trends and from the 531.74% surge in Jun 30 2023.

In the Healthcare sector 59 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 170.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 109
Healthcare Sector # 60
Overall # 170

Revenue TTM Y/Y Growth Statistics
High Average Low
115.34 %
 -8.54 %
-131.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 109
Sector # 294
S&P 500 # 1702
Cumulative Revenue growth Comment
Assuming the Dmk Pharmaceuticals's fiscal year would have ended in Sep 30 2023, Dmk Pharmaceuticals would have reprted above average annual Revenue surge of 128.81% year on year, of $ 4 millions.
This marks a slow-down of the companys growth trends and from the 531.74% surge in Jun 30 2023.

In the Healthcare sector 59 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 170.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 109
Healthcare Sector # 60
Overall # 170

Revenue TTM Y/Y Growth Statistics
High Average Low
115.34 %
-8.54 %
-131.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 109
Sector # 294
S&P 500 # 1702




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DMK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Adaptimmune Therapeutics Plc-0.16%$ -0.164 millions
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Vycor Medical Inc -0.44%$ -0.442 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Hologic Inc-0.81%$ -0.808 millions
Bionexus Gene Lab Corp -0.83%$ -0.831 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions


About Dmk Pharmaceuticals Revenue Growth Rates (DMK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dmk Pharmaceuticals Corp (CIK 887247).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001999371-23-000197
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dmk Pharmaceuticals Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.